[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606586":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":43,"collaborators":47,"id":50,"slug":18,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":30,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-MY6349 PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: 68Ga-MY6349 PET\u002FCT",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DIAGNOSTIC_TEST",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Deling Li, MD","STUDY_CHAIR",[24],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","+86 13810098236","lideling@bjtth.org",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Beijing","Beijing Municipality","100070","China",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Deling Li","Professor",[48],{"name":49,"class":6},"Peking Union Medical College Hospital","100606586",false,"NCT07177482","ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients","Inclusion criteria:\n\n* must be able to provide a written informed consent\n* radiologically presumed and\u002For histologically confirmed craniopharyngioma scheduled for resection\n* adequate clinical condition (Karnofsky performance status ≥70)\n\nExclusion criteria:\n\n* concomitant major central nervous system disorders\n* severe hepatic or renal dysfunction\n* history of severe allergy or hypersensitivity to intravenous radiographic contrast agents\n* claustrophobia precluding PET\u002FCT or MRI examinations\n* pregnancy or breastfeeding","ALL","14 Years","80 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"NA","This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.",[66],"Craniopharyngioma",[68,69],"Positron-Emission Tomography","Diagnosis","2025-09-10",{"date":72,"type":73},"2025-09-17","ACTUAL",{"date":75,"type":73},"2025-07-04",{"date":77,"type":60},"2026-12-31",{"name":45,"class":6},1]